Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan
Open Access
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 15, 55-63
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development (16lk0103005h0005)
This publication has 26 references indexed in Scilit:
- Efficacy of bezafibrate on fibroblasts of glutaric acidemia type II patients evaluated using an in vitro probe acylcarnitine assayBrain and Development, 2017
- The Biochemistry and Physiology of Mitochondrial Fatty Acid β-Oxidation and Its Genetic DisordersAnnual Review of Physiology, 2016
- Mitochondrial trifunctional protein deficiency in human cultured fibroblasts: effects of bezafibrateJournal of Inherited Metabolic Disease, 2015
- Rhabdomyolysis: Review of the literatureNeuromuscular Disorders, 2014
- Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: Evaluation by in vitro probe acylcarnitine assayMolecular Genetics and Metabolism, 2012
- Long-Term Follow-Up of Bezafibrate Treatment in Patients With the Myopathic Form of Carnitine Palmitoyltransferase 2 DeficiencyClinical Pharmacology & Therapeutics, 2010
- Bezafibrate for an Inborn Mitochondrial Beta-Oxidation DefectNew England Journal of Medicine, 2009
- Role of MB Isoforms (Isomers) in the Early Diagnosis of Acute Myocardial Infarction.Internal Medicine, 1994
- The MOS 36-Item Short-Form Health Survey (SF-36)Medical Care, 1993
- Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemiaAtherosclerosis, 1978